Skip to content

Non-Canonical Peptide Self-Assembly for Mitochondria-Specific Cargo Delivery

Sep 2026 · Journal of the American Chemical Society · 0 citations · 47 references

TL;DR

A minimalist, intrinsically mitochondria-targeting noncanonical tetrapeptide, X-GNNpY, comprising one glycine, two (S)-2-amino-3-(naphthalen-1-yl)-propanoic acid residues (N, and one phosphorylated tyrosine) is reported, which selectively accumulates in tumor-cell mitochondria through enzyme-instructed self-assembly.

Abstract

Targeting mitochondria is a promising strategy for precision tumor therapy, yet ligand-free mitochondrial drug delivery remains challenging. Here, we report a minimalist, intrinsically mitochondria-targeting noncanonical tetrapeptide, X-GNNpY, comprising one glycine, two (S)-2-amino-3-(naphthalen-1-yl)-propanoic acid residues (N), and one phosphorylated tyrosine (pY). Without external targeting ligands, X-GNNpY selectively accumulates in tumor-cell mitochondria through enzyme-instructed self-assembly. Conjugating chlorambucil (CLB) yields CLB-GNNpY, which efficiently redirects CLB to mitochondria. CLB-GNNpY exhibits good cellular selectivity, induces mitochondrial stress and immunogenic cell death, promotes M1-like macrophage polarization, and markedly enhances antitumor phagocytosis. This proof-of-concept study establishes noncanonical peptide self-assembly as a ligand-free supramolecular strategy for mitochondrial drug delivery and immune modulation in tumor therapy.

View source

Similar papers

Open access Sep 2026

DNA-Peptide Nanoassembly for Mitochondria-Specific and Programmable Subcellular Apoptotic Regulation.

Effective tumor cell apoptosis critically depends on the efficient delivery of pro-apoptotic agents to mitochondria. While mitochondria-targeted peptide-based nanoassemblies offer a promising platform for controllable delivery, achieving mitochondria-specific responses and programmable subcellular apoptotic regulation...

Fu-Qiang Zhang, Xi Hu, Yan-Ru Sun et al. · 0 citations
Sep 2026

Targeting mitochondrial G-quadruplex DNA with a theragnostic small molecule for cervical Cancer imaging and therapy.

Mitochondria are emerging as critical hubs for cancer therapeutics, yet the development of agents that simultaneously enable real-time imaging and targeted therapy remains a formidable challenge. Here we report LN1, a smart theranostic small molecule designed to selectively target mitochondrial G-quadruplex (mtG4) DNA...

Nuan Li, Wen-Bo Yan, Zhe Wang et al. · 0 citations
Open access Sep 2026

2-Aminoisobutylic Acid-Stabilized Helical Peptides for Selective Mitochondrial Gene Delivery.

Efficient gene delivery to mitochondria remains a major challenge in the development of organelle-targeted therapeutics. Here, we report the rational design and evaluation of helix stabilized mitochondria-targeting peptides (MTPs) via the incorporation of 2-aminoisobutyric acid (Aib), a noncanonical residue known to pr...

Kota Nomura, Kayo Terada, Yosuke Murakami et al. · 0 citations
Oct 2026

A self-assembled hydrophobic polymer tagged nanoplatform for membrane protein degradation and immunomodulatory drug delivery.

Tri@N is established as a dual-functional polymeric nanoplatform that integrates hydrophobic polymer tagging-mediated degradation of a membrane protein with therapeutic payload delivery, providing a versatile strategy for multimodal cancer therapy.

Seohee Lee, Mihyeon Park, Soyeon Jeon et al. · 0 citations
Oct 2026

Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains therapeutically challenging. Sorafenib, the standard first-line therapy for advanced HCC, suffers from poor aqueous solubility, non-specific biodistribution, dose-limiting toxicities, and the emergence of mitochondrial-mediated resistance. Here, we engineered a dual-targeted den...

Vikrantvir Jain, A. I. Dar, Ananya Biswas et al. · 0 citations
#gene editing Review Open access Oct 2026

Zein-based hybrid nanocarriers for non-viral gene delivery: A review.

Zein-based gene delivery remains preclinical and requires stronger mechanistic, cargo-specific and route-specific validation, and translational rationale for zein lies not in superior intrinsic transfection efficiency, but in route-specific protection, sustained release, hydrophobic drug co-loading and use as a biodegr...

Dua Alsinglawi, Enass Serry Moursy, Bilgesu Kasurka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.